Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis

被引:110
作者
Hanai, H
Watanabe, F
Yamada, M
Sato, Y
Takeuchi, K
Iida, T
Tozawa, K
Tanaka, T
Maruyama, Y
Matsushita, I
Iwaoka, Y
Kikuch, K
Saniabadi, AR
机构
[1] Hamamatsu Univ Sch Med, Dept Med, Hamamatsu, Shizuoka, Japan
[2] Fujueda Gen Hosp, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Med Ctr, Hamamatsu, Shizuoka, Japan
[4] Seirei Gen Hosp, Hamamatsu, Shizuoka, Japan
[5] Natl Tosei Hosp, Nagaizumi, Shizuoka, Japan
[6] Japan Immunores Labs, Takasaki, Gumma, Japan
关键词
ulcerative colitis; prednisolone; corticosteroid-dependent ulcerative colitis; granulocyte- and monocyte-adsorptive apheresis; steroid sparing;
D O I
10.1159/000080079
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim: Active ulcerative colitis (UC) is often associated with increased peripheral granulocytes and monocytes/macrophages which show activation behavior and prolonged survival time. Further, mucosal granulocyte level parallels intestinal inflammation and can predict UC relapse. Accordingly, our aim was to see if adsorptive granulocyte/monocyte apheresis (GMA) can promote remission and spare steroid in patients with steroid-dependent (SD) UC. Methods: 69 SD patients, at the time of relapse, were randomly assigned to groups I (n = 46) and II (n = 23). The mean dose of prednisolone (PSL) was 12 mg/day/patient, CAI (clinical activity index) 9.2 in both groups. Group I patients were given up to 11 GMA sessions over 10 weeks with Adacolumn; in group II, the mean dose of PSL was increased to 30 mg/day/patient. Results: At week 12, 83% of group I and 65% of group II patients were in remission, CAI in group I was 1.7 (p < 0.001) and in group II, 2.5 (p < 0.001). Further, during the 12 weeks of treatment, the cumulative amount of PSL received per patient was 1,157 mg in group I and 1,938 mg in group II (p = 0.001). Conclusions: GMA appeared to be an effective adjunct to standard drug therapy of moderately severe UC by promoting remission and sparing steroids. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:36 / 44
页数:9
相关论文
共 52 条
[21]   IL-5 and TNF-α participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis [J].
Lampinen, M ;
Carlson, M ;
Sangfelt, P ;
Taha, Y ;
Thörn, M ;
Lööf, L ;
Raab, Y ;
Venge, P .
DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (09) :2004-2009
[22]   INHIBITION OF APOPTOSIS AND PROLONGATION OF NEUTROPHIL FUNCTIONAL LONGEVITY BY INFLAMMATORY MEDIATORS [J].
LEE, A ;
WHYTE, MKB ;
HASLETT, C .
JOURNAL OF LEUKOCYTE BIOLOGY, 1993, 54 (04) :283-288
[23]   The key role of macrophages in the immunopathogenesis of inflammatory bowel disease [J].
Mahida, YR .
INFLAMMATORY BOWEL DISEASES, 2000, 6 (01) :21-33
[24]  
MCCARTHY DA, 1991, CLIN EXP IMMUNOL, V86, P489
[25]  
Meagher LC, 1996, J IMMUNOL, V156, P4422
[26]  
MEURET G, 1978, GASTROENTEROLOGY, V74, P501
[27]  
MEYERS S, 1983, GASTROENTEROLOGY, V85, P351
[28]   Regulation of production of soluble Fcγ receptors type III in normal and pathological conditions [J].
Moldovan, I ;
Galon, J ;
Maridonneau-Parini, I ;
Roman, SR ;
Mathiot, C ;
Fridman, WH ;
Sautès-Fridman, C .
IMMUNOLOGY LETTERS, 1999, 68 (01) :125-134
[29]   CR3 (CD11B/CD18) EXPRESSED BY CYTOTOXIC T-CELLS AND NATURAL-KILLER-CELLS IS UP-REGULATED IN A MANNER SIMILAR TO NEUTROPHIL CR3 FOLLOWING STIMULATION WITH VARIOUS ACTIVATING AGENTS [J].
MUTO, S ;
VETVICKA, V ;
ROSS, GD .
JOURNAL OF CLINICAL IMMUNOLOGY, 1993, 13 (03) :175-184
[30]   NEUTROPHIL AND MONOCYTE CELL-SURFACE P150,95 HAS IC3B-RECEPTOR (CR4) ACTIVITY RESEMBLING CR3 [J].
MYONES, BL ;
DALZELL, JG ;
HOGG, N ;
ROSS, GD .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (02) :640-651